Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Zai Lab rises on promising early data from cancer drug trial

** U.S.-listed shares of Chinese biopharma co Zai Lab Ltd
 ZLAB.O  up 6.7% to $35.21 premarket
    ** Co to present new data from early stage study of antibody
drug candidate to treat solid tumors at 2023 American Society of
Clinical Oncology Annual Meeting
    ** Says early data supports a solid tolerability profile and
preliminary antitumor activity
    ** There were no dose limiting toxicities as of the data
cut-off date in an evaluation of 10 patients
    ** Six patients achieved stable disease, in which cancer
neither increases or decreases in seveity or extent, and 3
patients show evidence of tumor regression
    ** Stock up 7.5% YTD

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))

Recent news on Zai Lab

See all news